midazolam has been researched along with Systemic Inflammatory Response Syndrome in 3 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Systemic Inflammatory Response Syndrome: A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever
| Excerpt | Relevance | Reference |
|---|---|---|
| "The recently published pharmacokinetic model for midazolam, quantifying the influence of maturation, inflammation and organ failure in children, yields unbiased clearance predictions and can therefore be used for dosing instructions in term neonates, children and adults with varying levels of critical illness, including healthy adults, but not for extrapolation to preterm neonates." | 3.88 | Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. ( Brussee, JM; de Hoog, M; de Wildt, SN; Jacqz-Aigrain, E; Knibbe, CAJ; Krekels, EHJ; Swart, EL; Tibboel, D; Valkenburg, AJ; van den Anker, JN; van Gerven, JMA; Vet, NJ, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zombori, L | 1 |
| Bacon, M | 1 |
| Wood, H | 1 |
| Chatterjee, F | 1 |
| Venkateswaran, R | 1 |
| Lampariello, S | 1 |
| Yoong, M | 1 |
| Brussee, JM | 1 |
| Vet, NJ | 1 |
| Krekels, EHJ | 1 |
| Valkenburg, AJ | 1 |
| Jacqz-Aigrain, E | 1 |
| van Gerven, JMA | 1 |
| Swart, EL | 1 |
| van den Anker, JN | 1 |
| Tibboel, D | 1 |
| de Hoog, M | 1 |
| de Wildt, SN | 1 |
| Knibbe, CAJ | 1 |
| Haitsma, JJ | 1 |
| Lachmann, B | 1 |
| Papadakos, PJ | 1 |
3 other studies available for midazolam and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Severe cortical damage associated with COVID-19 case report.
Topics: Acute Kidney Injury; Adolescent; Airway Extubation; Anticonvulsants; Blood Coagulation Disorders; Bo | 2021 |
Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.
Topics: Adult; C-Reactive Protein; Child; Critical Illness; Cytochrome P-450 CYP3A; Humans; Hypnotics and Se | 2018 |
Additives in intravenous anesthesia modulate pulmonary inflammation in a model of LPS-induced respiratory distress.
Topics: Acute Lung Injury; Adjuvants, Anesthesia; Anesthesia, Intravenous; Animals; Bronchoalveolar Lavage F | 2009 |